Dakota Gustafson1,2, Jason E Fish1,2,3, Jeffrey H Lipton4, Nazanin Aghel5. 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada. 3. Toronto General Hospital Research Institute University Health Network, Toronto, ON, Canada. 4. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. jeff.lipton@uhn.ca. 5. Division of Cardiology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. aghel@hhsc.ca.
Abstract
PURPOSE OF REVIEW: Oral tyrosine kinase inhibitors have revolutionized the treatment of chronic myelogenous leukemia, with many patients achieving major clinical and molecular responses without complications. While typically well-tolerated, clinical experience with tyrosine kinase inhibitors (particularly those of the second and third generations) has highlighted unanticipated associations with serious non-cancer adverse effects on various organs, particularly the cardiovascular system. RECENT FINDINGS: Herein, we review the current literature surrounding the major cardiovascular toxicities of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia, discuss potential mechanisms underpinning their development, and suggest future research directions to uncover novel ways to reduce cardiovascular events in patients treated with tyrosine kinase inhibitors. As a whole, while cardiovascular toxicities are well-documented, the mechanistic basis of these clinical observations remains poorly defined. In turn, to provide safe and effective treatment to all patients, it is necessary to close the knowledge gap regarding mechanisms that drive toxicity and elucidate the complex interactions that predispose specific individuals to these toxicities.
PURPOSE OF REVIEW: Oral tyrosine kinase inhibitors have revolutionized the treatment of chronic myelogenous leukemia, with many patients achieving major clinical and molecular responses without complications. While typically well-tolerated, clinical experience with tyrosine kinase inhibitors (particularly those of the second and third generations) has highlighted unanticipated associations with serious non-cancer adverse effects on various organs, particularly the cardiovascular system. RECENT FINDINGS: Herein, we review the current literature surrounding the major cardiovascular toxicities of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia, discuss potential mechanisms underpinning their development, and suggest future research directions to uncover novel ways to reduce cardiovascular events in patients treated with tyrosine kinase inhibitors. As a whole, while cardiovascular toxicities are well-documented, the mechanistic basis of these clinical observations remains poorly defined. In turn, to provide safe and effective treatment to all patients, it is necessary to close the knowledge gap regarding mechanisms that drive toxicity and elucidate the complex interactions that predispose specific individuals to these toxicities.
Authors: L L Remsing Rix; U Rix; J Colinge; O Hantschel; K L Bennett; T Stranzl; A Müller; C Baumgartner; P Valent; M Augustin; J H Till; G Superti-Furga Journal: Leukemia Date: 2008-11-27 Impact factor: 11.528
Authors: Mandy L Ballinger; Narin Osman; Kazuhiko Hashimura; Judy B de Haan; Karin Jandeleit-Dahm; Terri Allen; Lisa R Tannock; John C Rutledge; Peter J Little Journal: J Cell Mol Med Date: 2009-09-14 Impact factor: 5.310
Authors: Ruiqi Chen; Xing Liu; Arjun D Law; Solaf Kanfar; Dawn Maze; Steven M Chan; Vikas Gupta; Karen W Yee; Mark D Minden; Aaron D Schimmer; Andre C Schuh; Caroline J McNamara; Tracy Murphy; Anna Xu; Umberto Falcone; Jack Seki; Hassan Sibai Journal: Curr Oncol Date: 2020-12-22 Impact factor: 3.677
Authors: Ricardo Roa-Chamorro; Fernando Jaén-Águila; José Manuel Puerta-Puerta; Lucía Torres-Quintero; Pablo González-Bustos; Juan Diego Mediavilla-García Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379